On April 6, 2023 Domain Therapeutics ("Domain" or "the Company"), a clinical-stage biopharmaceutical company developing innovative drug candidates focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology, reported three posters the Company will be presenting at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, taking place April 14-19, 2023 in Orlando, Florida (Press release, Domain Therapeutics, APR 6, 2023, View Source [SID1234629855]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Based on clinical findings, including results of a large-scale meta-analysis, Protease-activated receptor 2 (PAR2) was identified as significantly associated with resistance to immune checkpoint blockade in cancer patients. With PAR2 representing a promising therapeutic target in oncology and immuno-oncology, Domain has developed a novel series of potent and selective PAR2 inhibitors which have demonstrated unique properties versus competitors.
The Company is also presenting further findings from its CCR8 depleting-antibody program, a promising target from which to derive novel immunotherapies. Based on the transcriptional analysis of tumor infiltrating immune cells, the G-protein coupled receptor CCR8 was found to be expressed on murine and human Tumor-infiltrating Tregs (TITR), a sub-family of immuno-suppressive cells which play a critical role in cancer, but not on proinflammatory effector T cells. Following a comprehensive in vitro benchmarking monoclonal antibody analysis, Domain identified key differentiating points of its candidates versus competitors.
Dr. Stephan Schann, VP Research at Domain Therapeutics, commented: "These new findings show the precise focus with which Domain is identifying promising new targets involved in immunosuppression, such as PAR2 and CCR8 receptors, which could lead to the development of more powerful therapeutic strategies. We are continuing to advance our leading GPCR precision research to identify first-in-class and best-in-class candidates in our efforts to unlock new possibilities in cancer and significantly improve patient outcomes."
Details of Domain’s AACR (Free AACR Whitepaper) abstracts which will be shown at the Orange County Convention Center, Orlando, Florida are provided below. All abstracts will be published in the online Proceedings of the AACR (Free AACR Whitepaper).
Title: Depleting hCCR8 mAb Therapy #1: Characterization of a broad collection of anti-hCCR8 mAbs
Abstract number: 2946 / 24
Poster session title: Therapeutic Antibodies 2
Location: Poster Section 23
Date and time: 17 April 2023 1:30 PM – 5:00 PM
Title: Depleting hCCR8 mAb Therapy #2: Selection of candidates for the development of innovative depleting anti-CCR8 therapeutic antibodies to control the immunosuppressive tumor microenvironment
Abstract number: 2945 / 23
Poster session title: Therapeutic Antibodies 2
Location: Poster Section 23
Date and time: 17 April 2023 1:30 PM – 5:00 PM
Title: Novel biased PAR2 inhibitors with best-in-class properties reduce resistance to both chemotherapy and immunotherapy in oncology models
Abstract number: 4961 / 7
Poster session title: Novel Targets and Pathways
Location: Poster Section 16
Date and time: 18 April 2023 1:30 PM – 5:00 PM